Last reviewed · How we verify
Insulin glargine plus insulin analogues
At a glance
| Generic name | Insulin glargine plus insulin analogues |
|---|---|
| Also known as | Insulin glargine plus short acting insulin analogues, Insulin glargine plus hypoglycemic agents |
| Sponsor | IRCCS San Raffaele |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (PHASE3)
- Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy (PHASE3)
- Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) (PHASE4)
- Human Versus Analogue Insulin in Patients After Pancreatectomy. (PHASE4)
- A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients (PHASE4)
- Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines (NA)
- Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (PHASE4)
- Extension to Study HMR1964A/3011 in Belgium (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin glargine plus insulin analogues CI brief — competitive landscape report
- Insulin glargine plus insulin analogues updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI